| Business Summary | | Impax
Laboratories
Inc.
(Impax)
is
a
specialty
pharmaceutical
company
focused
on
the
development
and
commercialization
of
specialty
generic
and
branded
pharmaceuticals,
utilizing
its
in-house
development
and
formulation
expertise.
As
of
December
31,
2000,
the
Company
had
four
Abbreviated
New
Drug
Applications
(ANDAs)
approved
and
eight
ANDAs
pending
at
the
FDA.
The
pending
ANDA
filings
are
for
generic
versions
of
branded
pharmaceuticals
whose
2000
U.S.
sales
were
approximately
$5.5
billion.
Impax
has
approximately
20
other
products
it
intends
to
file
as
ANDAs
in
various
stages
of
development.
The
Company
has
three
branded
projects
under
development.
The
Company
expects
to
file
its
first
application
from
these
projects
in
the
second
half
of
2001.
The
Company
currently
markets
16
generic
pharmaceuticals. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IPXL
is
engaged
in
the
development
of
generic
and
branded
pharmaceutical
products.
For
the
six
months
ended
6/30/01,
revenues
decreased
52%
to
$2.9
million.
Net
loss
before
accounting
change
increased
24%
to
$11.5
million.
Revenues
reflect
lower
sales
due
to
the
discontinuation
of
certain
products.
Higher
loss
reflects
a
negative
gross
margin
due
to
unabsorbed
costs
of
the
excess
capacity
and
start-up
operating
costs
of
a
new
plant. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Charles Hsiao, Ph.D., 56 Chairman,
Co-CEO | $122K | Barry Edwards, 43 Co-CEO | 225K | Larry Hsu, Ph.D., 51 Pres,
COO | 122K | Cornel Spiegler, 55 CFO | 167K | David Doll Sr.
VP of Sales and Marketing | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|